Survival Outcomes
The five-year OS throughout the time-period of 1997-2013 was
63% (95% CI: 53 – 74%) while
EFS at five years was observed to be 59% (95% CI: 49 – 71%)
(Figure 2A ). The 5-year OS and EFS estimates for those
diagnosed post-2008 were observed to be 47% (95% CI: 33 – 68%) and
42% (28 – 62%), and the 5-year OS and EFS for those diagnosed
pre-2008 were 74% (95% CI: 62 – 88%) and 72% (95% CI: 60 – 86%),
respectively (Figure 2B ). Five-year EFS rates by histology
were: desmoplastic/nodular 66% (95% CI: 43-100%), anaplastic 20%
(95% CI: 6-69%), classic 55% (95% CI: 36-84%), or other/undefined
69% (95% CI: 56-84%) (Figure 2C ). Five-year OS rates by
histology were: desmoplastic/nodular 74% (95% CI: 52 – 100%),
anaplastic 30% (95% CI: 12 – 77%), classic 54% (95% CI: 34 –
83%), or other/undefined histology 71% (95% CI: 58 – 86%) . M-stage
information was only available for those diagnosed post-2008; in this
subgroup, the 5-year EFS for those with no metastases at diagnosis (M0)
was 54% (95% CI: 36 – 81%) and for those with observed metastases
(M1+) was 13% (95% CI: 2 – 78%) (Figure 2D). Lastly, the
five-year OS rate for residual tumors less than 1.5cm2 was 50% (95%
CI: 32 – 79%) and 44% (95% CI: 26 – 77%) for residual tumors
greater than 1.5cm2.